- NASDAQ:SRNE jumps 2.68% on Thursday amidst a broader market bounce back.
- Promising results from COVI-DROPS antibody tests show investors some optimism.
- Several other treatments from Sorrento are coming down the pipeline.
NASDAQ:SRNE has finally provided investors and Wall Street with some optimism as the San Diego based biotech firm reported some early positive results from its COVID-19 treatment studies. Shares rose by 2.68% during Thursday’s trading session as the major markets rallied after three straight days of investor selloffs. Sorrento’s stock is now sitting at $7.28 which represents a 35% decline over the past month after investors began to jump ship without any news on its pending coronavirus treatments.
The big announcement from Sorrento revolves around its intranasal treatment for COVID-19 called COVI-DROPS which returned encouraging results when tested on hamsters who were infected with the SARS-CoV-2 virus. The agent is similar to the treatment previously tested called COVI-AMG which is an intravenous method of antibody administration. Animals who received COVI-AMG displayed noticeable differences as early as Day 5 following treatment. For COVI-DROPS, the hamsters surprisingly reacted positively as early as Day 2, showing reduced symptoms of COVID-19 as well as limited weight loss. Sorrento is hopeful that if the treatment has the same effect on humans in the next stage of clinical trials, that COVI-DROPS could be easily accessible and reduce unnecessary visits to hospitals.
SRNE stock price news
While Sorrento’s news is promising, actual distribution to humans may be a long way off. The treatments still have to pass through human testing as well as FDA approval, something several larger pharmaceutical companies like Gilead Sciences (NASDAQ:GILD) have already obtained. Sorrento also has a large amount of debt on its balance sheet as the company is quite literally spending hundreds of millions of dollars to remain in operation, something that should not be seen as sustainable for the long-term.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD trims losses and approaches 1.0800 after US data
The US Dollar renewed its bullish momentum on Tuesday, pressuring EUR/USD and keeping the pair under the critical 1.0800 threshold following the release of US ISM Manufacturing PMI and JOLTS readings.
GBP/USD meets support around 1.2880, USD remains strong
After bottoming out around the 1.2880 region, GBP/USD now manages to attempt a bounce and flirt with the 1.2900 zone in the wake of weaker-than-expected US data releases.
Gold looks range bound above $3,100
Gold is easing from its fresh record high near $3,150 but remains well supported above the $3,100 mark. A generalised pullback in US yields is underpinning the yellow metal, as traders stay on the sidelines awaiting clarity on upcoming US tariff announcements.
Dogecoin bulls defend lifeline support as risk-off sentiment continues
Dogecoin trades at $0.1731 during early American hours on Tuesday after recovering from Monday’s support at $0.16. The leading meme coin faced negative headwinds early in the week as investors reacted to comments by Tesla CEO Elon Musk, who heads the special Department of Government Efficiency (D.O.G.E.) in the US.
Is the US economy headed for a recession?
Leading economists say a recession is more likely than originally expected. With new tariffs set to be launched on April 2, investors and economists are growing more concerned about an economic slowdown or recession.
The Best brokers to trade EUR/USD
SPONSORED Discover the top brokers for trading EUR/USD in 2025. Our list features brokers with competitive spreads, fast execution, and powerful platforms. Whether you're a beginner or an expert, find the right partner to navigate the dynamic Forex market.